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Abstract
Aims/Background This study measures the performance of
the health system in 165 countries and its relationship with
public financing.
Methods We use value efficiency analysis (VEA), a
refinement of data envelopment analysis (DEA), to measure
the efficiency of the health systems using data on healthy
life expectancy and disability adjusted life years as health
outcomes. Expenditure on health and education are used as
inputs to the health system.
Results The group of high income OECD countries shows
the largest indexes of efficiency and also the lowest
dispersion. In contrast, low income countries also have
the most inefficient health systems, which implies that there
are more opportunities for improvement. The average
efficiency score is 0.96 for high income countries, 0.83
for upper-middle income countries, 0.86 for lower-middle
income countries and only 0.76 for low income countries.
Only 17 countries have a score equal to 1 and therefore are
completely efficient and can be taken as referents. The
index of efficiency is found to be positively associated with
government expenditure on health as a percentage of total
expenditure on health.
Conclusions The analysis of the results shows that the
public share in health expenditure and the weight of health
expenditure in public budgets are two factors positively
associated with the performance of the health systems. The
study also highlights the advantages of using VEA over
DEA in the measurement of performance.
Keywords Data envelopment analysis . Value efficiency
analysis . Health system performance . Health outcomes
Introduction
The increasing efforts of rich and developing countries to
improve the quality and quantity of health services call for
an objective and accurate assessment of the performance of
their health systems. Both policy makers and citizens
demand the best possible outcomes from the health system,
given the considerable amount of resources devoted to it.
Cumulative evidence shows that rich countries are installed
in the diminishing returns zone of the production function
in what has been named flat-of-the-curve medicine
(Enthoven 1980; Hertzman 1999; Fusch 2004). In these
countries, increasingly costly innovations and services can
barely achieve modest improvements in the general health
level of the population. The debate suggests that redirecting
resources from flat-of-the-curve medicine to other programs
that would promote healthy habits or education could perhaps
make a better contribution to health outcomes in rich
countries.
On the other hand, the returns that modest investments in
health services can produce in underdeveloped countries
can be dramatically important in terms of lives saved,
increases in life expectancy and improvements in living
conditions. However, the magnitude of these effects also
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critically depends on the way in which resources are
employed. Basic vaccine programs, for instance, can save
thousands of lives in these countries. With extremely
limited resources these countries cannot aspire today to
many sophisticated and costly health technologies that
would have a much lesser impact on the population. Again,
the way in which resources are allocated to their most
productive uses in terms of improving the general health
status of the population may vary greatly from one country
to another. Measuring the efficiency with which health
resources are transformed into health outcomes in different
countries can indicate the countries that can serve as
referents and indicate the opportunities for improvement
in the other, less efficient countries.
Unfortunately, the measurement of productive efficiency
in health care is a far from easy task. Traditionally, the main
difficulty has been the correct measurement of the outcome
of the health system (Kooreman 1994). The usual approach
is to use measurable intermediate indicators of the services
provided (outputs), which are assumed to have a fundamental
impact on the health status of the population (outcome).
Health system outcomes may be defined as those changes in
the health status of the population that can be attributed to
spending on health care (Häkkinen and Joumard 2007). The
World Health Organization database reports information on
many variables that conform to this definition (life expectancy,
infant mortality, inequality in access, prevalence of certain
diseases, etc.) for a broad sample of countries. Although there
may be some controversy regarding the appropriateness of
some of these variables as relevant outcomes of the health
system (Häkkinen and Joumard 2007), most analyses at the
system level have relied on the use of life expectancy and
infant mortality to approximate the outcomes of the health
system (Or 2000; WHO 2001; Retzlaff-Roberts et al. 2004;
Afonso and St. Aubyn 2005). However, it can be argued that
while infant mortality is a very dramatic problem in
underdeveloped countries, it is no longer a relevant issue in
most developed countries.
The measurement of health efficiency at the system level
of analysis is also subject to a second problem. The health
status of a country’s population is not only affected by
expenditure on health services. Many other factors related
to the social, economic and natural environment also play
an important role (Naylor et al. 2002). Therefore, influences
external to the health system must be accounted for in order
to provide accurate estimations of performance. Among
these external factors, education has been widely recog-
nized as the main driver of health status (Ross and Wu
1995; Grossman and Kaestner 2004; Grossman 2005;
Cutler and Lleras-Muney 2006). Educated people are in a
better position to interpret and evaluate information and are
therefore able to make better choices that improve and
preserve health conditions.
In recent years a variety of research studies have been
published that attempt to measure the efficiency of health
systems across the world. Most of these restrict the sample
to the OECD member countries and apply non-parametric
frontier measurement techniques such as data envelopment
analysis (DEA) or free disposal hull (FDH) (Retzlaff-
Roberts et al. 2004; Räty and Luoma 2005; Afonso and
St. Aubyn 2005; Lauer et al. 2004). On the other hand,
Evans et al. (2001) relied on parametric frontier estimation
techniques and covered a wide sample of 191 countries.
The most influential study was carried out by the World
Health Organization in the 2000 World Health Report
(WHO 2001). In this case the analysis included 191
member countries, and a synthetic index was constructed
weighting five dimensions representing the goals of the
health systems. In this paper, we apply analytical frontier
techniques from the DEA family to measure the performance
of the countries included in the WHO sample. In doing so, we
use information on health and non-health inputs and health
outcomes.
The extreme flexibility of DEA and its ability to handle
multiple outputs and inputs in the specification of the
production process explains its extensive use in the
measurement of health efficiency (Hollingsworth et al.
1999; Puig 2000; Worthington 2004). However, DEA also
has some drawbacks that severely limit its application in
practice. One of the most important limitations of DEA is
its low discriminatory power, especially when many
dimensions are taken into account and the sample size is
limited (Ali 1994). In these cases, DEA results show a
considerable number of efficient DMUs (decision-making
units), even though some of them would be considered as
low performers under closer inspection of the data. These
DMUs obtain a score of 100% simply because they are not
comparable to the rest of the sample in one or more
dimensions. In fact, the DEA score is a weighted index of
inputs and outputs, and there is total flexibility with regard
to the weights that can be assigned to each country. In the
WHO World Health Report 2000, the five health goal
dimensions received fixed weights for all the countries in
the sample. DEA does just the opposite: there is complete
freedom with regard to the weights assigned to each
country, and the country’s performance is compared to that
which would be achieved by other countries using the same
weights. In fact both approaches may seem to be extreme
cases. Some degree of flexibility in order to capture
differences in specific country goals or values may be
desirable (Richardson et al. 2003), but not to the extent of
preventing meaningful comparisons.
A recent advance in DEA methodology, namely value
efficiency analysis (VEA), provides a way of dealing with
this problem, though at the cost of an increased level of
analytical complexity. This technique is based on DEA, but
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adds a constraint on how input and output weights can be
chosen for the different countries within the sample. As a
result, VEA significantly improves both the discriminatory
power of DEA and the consistency of the weights upon
which the evaluation is based. We will use VEA to obtain
the final performance scores for the health systems.
Some policy implications can also be derived from the
performance indicators obtained for the countries in the
sample. In particular, we will focus on the relationship
between the commitment of governments towards financing
the health system and its performance. While systems
dominated by private provision of health services may be
more efficient in producing and delivering services, they
also can incur higher administrative costs than statutory
health insurance (Thomson and Mossialos 2004). In turn,
public provision of health can better provide access to basic
services for a larger fraction of the population. If this is so,
we should find a positive relationship between the
estimated indicator of performance and variables that reflect
the commitment of public resources to the health system.
The rest of the paper is structured as follows. “Methods”
briefly reviews the VEA model as an extension of
conventional DEA. “Data” presents the data, and “Results”
discusses the empirical results. Concluding remarks are
provided in the final section.
Methods
To compute the VEA efficiency scores, we must first obtain
the DEA frontier for the countries in the sample. The DEA
frontier identifies the countries that would be considered
completely efficient under certain (conservative) assumptions.
Even though there are many variants of DEA programs, in this
paper we follow the traditional specifications of Charnes et al.
(1978) for the constant returns to scale frontier (CRS) and
Banker et al. (1984) for the variable returns to scale frontier
(VRS). For the orientation of the efficiency model, we chose
an output orientation because we believe that the main concern
of governments and citizens regarding health during recent
decades has been to improve the quality and quantity of health
services and not cost containment. The CRS DEA model with
an output orientation requires solving the following mathe-
matical program for each DMU i in the sample:
min
PM
m¼1
vmxim
PS
s¼1
usyis
s:t :
PM
m¼1
vmxjm
PS
s¼1
usyjs
 1 ; 8j
us; vm  0 ; 8s;m
ð1Þ
where xim represents the consumption of input m by DMU i,
yis represents the production of output s by DMU i, vm is the
shadow price of input m, and us is the shadow price of output
s. The program finds the set of shadow prices that minimizes
the production cost of unit i with respect to the value of its
product, conditioned on obtaining ratios larger than or equal
to 1 for all the other DMUs in the sample. If DMU i is
efficient, the optimal shadow prices will give the minimum
possible value of the ratio, i.e., 1. Inefficiency would be
reflected by a value greater than 1 for the objective function.
The fractional program (1) entails some computational
complexities. Thus, it may be preferable to solve the
following equivalent linear program:
min
PM
m¼1
vmxim
s:t :
PS
s¼1
usyis ¼ 1
PS
s¼1
usyjs 
PM
m¼1
vmxjm  0 ; 8j
us; vm  0 ; 8s;m
ð2Þ
This program finds the shadow prices that minimize the
cost of DMU i, but normalizing the output value to 1. If
DMU i is efficient it will obtain a cost equal to 1, while if it
is inefficient it will obtain a value greater than 1. If DMU i
is inefficient then the solution to the linear program must
identify another DMU in the sample that obtains the
minimum cost of 1 with the shadow prices that are most
favourable to DMU i. Program (2) is solved for every DMU
in the sample, providing each unit with its most favorable
set of shadow prices for inputs and outputs and the
corresponding scores of relative efficiency. For ease of
interpretation, it is common to use the inverse of the
objective function in (2) as the efficiency score. Therefore,
the score is bounded within the (0,1] interval, and values
lower than 1 reflect the degree of productive inefficiency.
Banker et al. (1984) relax the CRS assumption modifying
linear program (2) to allow for VRS:
min
PM
m¼1
vmxim þ ei
s:t :
PS
s¼1
usyis ¼ 1
PS
s¼1
usyjs 
PM
m¼1
vmxjm  ei  0 ; 8j
us; vm  0 ; 8s;m
ð3Þ
where the intercept ei is added to relax the CRS condition
that forced the objective function to pass through the origin
in (2). In program (3), that condition will only be satisfied if
e*i ¼ 0. For values greater than or smaller than 0, the
reference on the frontier for the DMU will be located in a
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local zone with decreasing or increasing returns to scale
respectively. Most productive activities are subject to
variable returns to scale, and health is just one of them. For
example, it is relatively easy to achieve large improvements
in the health level of the population of poor countries with a
very limited expenditure on vaccination campaigns, infor-
mation campaigns regarding common diseases, etc., so that
increasing returns are observed within these countries. The
opposite occurs in rich countries. Obtaining additional
increases in the health status of the population in rich
countries is much more expensive because of decreasing
returns (flat-of-the-curve hypothesis). Thus, we consider that
the VRS frontier is the most appropriate for evaluating health
efficiency in order to avoid scale problems in the efficiency
scores due to effects of the large differences in the sizes of
the countries. To further avoid scale problems, we will use
data that are measured as ratios or per-capita values, which
eliminate the size component in the data.
A distinctive feature of DEA is the absolute flexibility in
the way the linear program can assign weights (shadow
prices) to each particular DMU in the sample. Recall that
the program is solved independently for each DMU and
that shadow prices for inputs and outputs may then be
completely different from one DMU to another. The main
argument in defense of the extreme weight flexibility in
DEA is that this has the advantage of providing an
evaluation of the inefficiency of each DMU under its most
favorable scenario. However, extreme flexibility is also the
object of criticism because it often produces an extreme
inconsistency in the values of the shadow prices across
DMUs. To avoid this inconsistency the DEA literature has
suggested some solutions to restrict the range of acceptable
values for those weights (Thompson et al. 1996; Dyson and
Thanassoulis 1988; Allen et al. 1997; Roll et al. 1991;
Wong and Beasley 1990; Pedraja et al. 1997; Sarrico and
Dyson 2004).
In turn, the problem of weight restriction methods is that
they require making value judgments about the range of
shadow prices that is considered appropriate. In order to
facilitate the implementation of weight restrictions in
practice, Halme et al. (1999) proposed an alternative
methodology under the name value efficiency analysis
(VEA). The objective of VEA is to restrict weights using a
simple piece of additional information that must be
supplied by an outside expert. The most notable difference
between VEA and conventional methods of weight restric-
tion is that instead of establishing appropriate ranges for
shadow prices, the expert is simply asked to select one of
the DEA-efficient DMUs as his most preferred solution
(MPS). Once the MPS is selected, the standard DEA
program is supplemented with an additional constraint that
forces the weights of the DMU under evaluation (i) to make
the MPS (o) efficient. In other words, the new linear
program requires that the optimal shadow prices selected
for DMU i must also be good for the MPS in the sense that
they ensure that the MPS is on the frontier. As this
requirement is made for all the DMUs in the sample, the
optimal sets of shadow prices for all the linear programs
must make the MPS efficient. The use of the MPS therefore
ensures a high degree of consistency in the sets of shadow
prices across DMUs. An immediate effect of the VEA
constraint is that DMUs that obtained a DEA score of 1
simply because they had an extreme value in one input or
output will only obtain a VEA score equal to 1 if they can
withstand the additional comparison with the MPS.
The VRS VEA program with an output orientation can
be expressed as follows:
min
PM
m¼1
vmxim þ ei
s:t :
PS
s¼1
usyis ¼ 1
PS
s¼1
usyis 
PM
m¼1
vmxjm  ei  0 ; 8j
PM
m¼1
vmxom þ ei 
PS
s¼1
usyos ¼ 0
us; vm  0 ; 8s;m
ð4Þ
Program (4) is identical to program (3) with the MPS
constraint added. Thus, the MPS (o) must obtain a value of 1
with the shadow prices of DMU (i). Indirectly, this
requirement restricts the permissible range of shadow prices
to the range that makes the MPS (o) efficient. We used the
software LINGO to solve the DEA and VEA programs in our
study. While many packages are pre-programmed to solve
DEA, we are not aware of any that can solve VEA. However,
any mathematical programming software can be used.
A controversial issue in VEA is how to select the MPS
(Korhonen et al. 1998). Our empirical setting is designed to
evaluate the efficiency of countries regarding their health
achievements. In this context, it would be difficult to find
an expert that could provide the MPS. We propose a new
alternative method that avoids supplying any external
information. We will run various VEA analyses considering
each of the countries that are DEA efficient as the MPS.
Then, we will compute the average reduction in the
variation of the shadow prices of the variables included in
the VEA model. The country that achieves the greatest
reduction in the variation of shadow prices will be our
selected MPS. This approach has two advantages. First, it is
objective and does not require the implication of an outside
expert. Second, it obtains the greatest possible congruence
in the shadow prices from the set of linear programs that are
computed to calculate the value efficiency scores. This
seems highly consistent with the objective we were
pursuing with the implementation of VEA instead of DEA.
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Data
We are interested in measuring value efficiency scores for
all the countries in the WHO database for the year 2004.
However, the required data were not available for some of
the countries in the database, and therefore they were
excluded from the analysis. The final sample includes a
total of 165 countries, which is sufficiently large for the
techniques we will use and representative of the vast
majority of the world’s population. While we followed the
existing literature in order to choose the variables that could
reasonably approximate the relevant dimensions of health
production at the system level of analysis, we are
innovative in the precise specification of the outputs.
To approximate the output of the health system, the
specification that has been common in previous empirical
research has relied on life expectancy and infant mortality
rates (Retzlaff-Roberts et al. 2004; Afonso and St. Aubyn
2005; Räty and Luoma 2005). Life expectancy is a variable
that is widely available and can be considered as a long run
global result of the health system of a country (Evans et al.
2001). Countries with poor access to health services, poor
quality of health care centers and physicians and low
expenditure on medicines will, in general, have a low
average life expectancy. In contrast, it is reasonable to
assume that many (though not all) health care services
should translate into a higher life expectancy for the
population. However, it could be argued that the living
conditions of these additional years of life should also be
taken into account when specifying the goals of a health
system. Thus, adding life to years may emerge as a more
reasonable health system goal. We believe that the variable
Healthy Life Expectancy provided by the WHO for the year
2002 covers both aspects, namely adding years to life and
life to years, in that it measures the expectancy of life in
good living conditions.
The second output variable that has been widely used in
previous literature is infant mortality. This variable is an
outcome of a health system and also an indicator of
inequality in access to resources. However, we believe that
this variable is not relevant for many developed countries,
since infant mortality is no longer an issue in those
countries. Instead, we propose using a more general
variable that is relevant for all the countries of the sample
and that indirectly captures the effects of infant mortality in
those countries in which it is an important problem. The
variable we will use is provided by the WHO for the year
2004 with the name Disability Adjusted Life Years
(DALY). It is a measure of the years lost due to premature
death and also includes the equivalent years lost due to
disability. In particular, we use the age-standardized DALY
rates per 100 inhabitants. Obviously, this variable must be
transformed in order to use it as an output in a DEA
specification (i.e., a larger value must indicate a better
performance). We therefore take the inverse of the variable
and multiply by 100 for ease of interpretation. This
transformed variable can be interpreted as the number of
people in the population that corresponds to the loss of a
year of life to disability or premature death. For example,
Ghana has a value of 33.3 for the original DALY variable,
which means that 33.3 years are lost to death or disability
per 100 members of the population. Our inverse variable
takes the value 3, which means that there is 1 year of life
lost to death or disability for every three people in the
population. The higher this value is, the better the
performance of the health system. While in the DEA and
VEA models we will use this transformed variable, in the
tables summarizing results we will use the original DALY
variable in order to improve the readability of the paper.
The input variables should capture the magnitude of the
resources committed to health production services and other
environmental or social factors that influence the health
status of the population. The resources devoted to the health
system are approximated by per capita total expenditure in
health in purchasing power parity of $US (PPP). Using PPP
expenditure facilitates cross-country comparisons (Gupta
and Verhoeven 2001). However, health resources are not
the only input involved in the health production process. It
has been argued that the social environment greatly
influences the health status of the population (Naylor et
al. 2002). An appropriate and available proxy for the
beneficial influences of the social environment is the level
of education. The basic argument is that a person that is
better educated would make healthier choices (Cowell
2006). Additionally, education is an excellent proxy for
other social dimensions that may influence health (nutri-
tion, hygiene, use of health services, working conditions,
etc.). As an indicator of the level of education we use the
School Life Expectancy (Years). This variable was taken
from the UNESCO online database.
Given the enormous disparities that exist among
countries, we decided not to pool all the countries of the
sample under the same production frontier. Instead we
separated the sample into four sub-samples of countries
based on the degree of development of the country. We
followed the classification made by the World Bank that
separates countries into four groups according to gross
national income per capita. The groups are low income
($935 or less), lower-middle income ($936–$3,705), upper-
middle income ($3,706–$11,455) and high income
($11,456 or more). In order to provide a more accurate
comparison of countries, high income non-OECD countries
were included in the group of upper-middle income
countries. This subgroup of countries is composed of those
such as Brunei, Bahrain, Barbados, Cyprus, Kuwait, etc.,
that are more similar to the group of upper-middle income
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countries in terms of the variables used as an input in our
DEA model (education and per capita expenditure in
health). Indeed, they are not comparable to the group of
OECD high income countries in terms of health expenditure
or health results.
Table 1 succinctly describes the variables used as inputs
and outputs in our empirical analysis for the four groups of
countries. It is clear from the table that there is great
variation across countries in every dimension of the health
production model, as reflected by the standard deviations
(SD). Perhaps the most striking differences concern the
DALYs, which represent the years lost to premature death
or disability per 100 members of the population. The
minimum of eight corresponds to Japan and reflects the
situation of most developed countries in the high income
group. In contrast, Zimbabwe with 82.8 is the most extreme
example of an underdeveloped country in the low income
group that also suffers the effects of violence. If we look at
an input dimension we obtain a similar picture. The
Democratic Republic of the Congo is the country that
spends less in health per capita ($15 PPP) and is
representative of the situation in most underdeveloped
countries, most of which are in Africa and Asia. On the
opposite extreme, the USA spends $6,014 PPP followed by
Luxembourg with $5,317 PPP, representing the situation in
the developed and rich part of the world. However, these
figures do not guarantee that this money is being spent
efficiently on the production of relevant health outcomes in
any of these countries. The relationship between resources
and outcomes is what gives us the indicator of efficiency.
Results
The DEA model was run separately for each of the four
groups of countries to obtain an initial efficiency frontier
for each group. This is a necessary step to identify which
countries are located on the frontier and can thus be
considered as candidates to be the MPS for the VEA
analysis. Table 2 summarizes the DEA results for the 165
countries in the four income groups considered, further
classified into broad geographical areas. High income
OECD countries show the largest average efficiency and
also the lowest dispersion. In contrast, low income countries
have the lowest average and the largest dispersion. These
results show that the health systems in high income countries
have more similarities among them than the health systems in
low income countries. Therefore, when comparisons are made
within each group, the much larger dispersion for low income
countries also reflects larger distances to the best practice
frontier. This means that there is more room for improvement
in low income countries than in high income countries, a
finding consistent with the flat-of-the-curve hypothesis.
With respect to geographical areas, European countries
are among the most efficient on average, closely followed
by American, Oceanic and Asian countries. Since most low
Average Min Max SD
High income countries
Total expenditure in health PPP ($) 2,830.2 1,058 6,014 1,137.8
School life expectancy 16.1 13.6 20.4 1.5
Healthy life expectancy (2002) 70.9 64.9 75 2.2
Age std. DALYs per 100 10.7 8 15 1.5
Upper-middle income countries
Total expenditure in health PPP ($) 724.4 236 4,457 646
School life expectancy 13.4 9.6 16.5 1.5
Healthy life expectancy (2002) 62.1 35.7 71.4 6.39
Age std. DALYs per 100 18.6 9.7 53.4 9
Lower-middle income countries
Total expenditure in health PPP ($) 251.6 31 588 149.5
School life expectancy 11.1 3.68 14.3 2.3
Healthy life expectancy (2002) 55.7 31.4 64.4 8.3
Age std. DALYs per 100 24.8 15.5 65 10.8
Low income countries
Total expenditure in health PPP ($) 70 15 188 43.5
School life expectancy 7.8 3.5 12.4 2
Healthy life expectancy (2002) 44.5 28.6 61.4 8
Age std. DALYs per 100 41.5 17 82.8 14.4
Table 1 Descriptive statistics of
inputs and outputs
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income countries are located in Africa, it is not surprising
that this continent is the least efficient in terms of health
attainment. It is noticeable though that more than one third
of the DEA-efficient countries are also located in Africa.
On the other hand, we were not able to find any efficient
country within the North American area. It can also be
noticed that the standard deviation is very high in Africa,
whereas it is moderate in Europe and America. It is also
noticeable that all the Asian countries included in the high
income group (Japan and Korea) are on the frontier,
whereas the other two frontier countries are European
(Luxembourg and Slovakia).
Overall, the minimum efficiency score is obtained by
Botswana in Southern Africa. With 35.7 years of Healthy Life
Expectancy and 53.4 DALYs per 100 members of the
population, this country obtains an index of just 0.53, which
means that an improvement of 88% in health outcomes could
be achieved with a better use of resources. In this particular
case, this improvement would add 31.6 more years of healthy
life and avoid 25.1 DALYs per 100members of the population.
A total of 26 countries in the sample obtain a DEA score
equal to 1, which means they cannot make any (relative)
improvement, given the data observed and the structure of
the DEA programs that generate the best practice reference
frontier. Some of these are countries with favorable health
outcomes, given the resources deployed in health production
and their standards of comparison. However, other countries
are on the frontier simply because DEA is very flexible in
evaluating countries with extreme data. These countries may
be assigned unreasonable weights to inputs and/or outputs in
the DEA program to reach complete DEA efficiency. For
example, the Democratic Republic of the Congo is the country
with the lowest per capita expenditure on health, and this
makes it DEA-efficient regardless of its Healthy Life
Expectancy or DALY figures. The DEA program will assign
an extremely high weight to per capita expenditure on health,
and no other country could then be comparable to the
Democratic Republic of the Congo.
In our view, the presence of these “extreme data”
countries on the DEA frontiers only provides evidence for
the important limitations of DEA. Many countries with
poor results are considered efficient simply because there is
no other country that does better in some dimension of the
production setting. In other words, the flexibility of the
weights allows some countries to be assigned a very low
value in those dimensions in which they perform poorly
and a high value in those dimensions in which they perform
better. As we noticed before, the Democratic Republic of
the Congo achieves full DEA efficiency because of the
extremely high weight given to health expenditure. It would
not matter if this country reduced its life expectancy by one
half: it would still be DEA-efficient.
n Average Min Max SD Efficient
High income 27 0.964 0.923 1.00 0.02 4
Asia 2 1.00 1.00 1.00 0.0 2
Europe 21 0.963 0.931 1.00 0.02 2
North America 2 0.942 0.924 0.961 0.03 0
Oceania 2 0.967 0.965 0.968 0.00 0
Upper-middle income 50 0.928 0.530 1.00 0.08 6
Africa 7 0.802 0.530 0.973 0.16 0
Asia 13 0.949 0.858 1.00 0.05 3
Europe 11 0.955 0.916 1.00 0.02 1
North America 1 0.968 – – – 0
Latin America and Caribbean 17 0.946 0.883 1.00 0.04 2
Oceania 1 0.900 – – – 0
Lower-middle income 45 0.924 0.536 1.00 0.10 8
Africa 13 0.872 0.536 1.00 0.17 4
Asia 14 0.946 0.845 1.00 0.04 3
Europe 4 0.968 0.920 0.992 0.03 0
Latin America and Caribbean 10 0.936 0.875 0.989 0.04 0
Oceania 4 0.941 0.838 1.00 0.07 1
Low income 43 0.843 0.537 1.00 0.13 8
Africa 31 0.811 0.537 1.00 0.13 5
Asia 11 0.922 0.798 1.00 0.08 2
Oceania 1 1.00 – – – 1
Total 165 0.911 0.530 1.00 0.10 26
Table 2 Summary of DEA
results by income and
geographical areas
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To increase the discriminatory power of DEA and
achieve a higher degree of congruence in the shadow
prices assigned to the different countries in the DEA
programs, we solved 26 VEA programs using as MPS
each of the 26 countries appearing on the DEA-efficient
frontiers. As before, the analysis was carried out separately
for each income group. For each VEA analysis we
computed the coefficient of variation of the weights of
each input and output and the average coefficient of
variation. The country that achieved the lowest average
was taken as the MPS. These countries were Japan for the
high income group, Oman for the upper-middle income
group, Algeria for the lower-middle income group and the
Solomon Islands for the low income group.
The VEA constraints produce more coherent results in
terms of the weights selected for each country in the DEA
program to justify its index of efficiency. The reductions in
the coefficients of variation of the weights within the
different groups of countries are 15% (high income), 77%
(upper-middle income), 70% (lower-middle income) and
69% (low income). The reductions are notable in all groups
except for the group of high income countries. Also, the
discriminatory power of DEA is enhanced with the VEA
specification. Of the 26 countries that form the DEA
frontiers, only 17 remain after the VEA constraints are
added to the linear programs. Again, the gains in
discriminatory power are higher for the three groups with
lower income. The group of high income countries
maintains its four DEA-frontier countries on the VEA
frontier. This means that within the high income group
there is less internal variation, and adding a constraint to
add coherence to the weights is of little help since the
internal coherence of the DEA results was already very
high. In fact, in the group of high income countries there
are no differences in the performance scores obtained with
DEA and VEA. In contrast, VEA significantly improves the
results of the DEA analysis in the other three groups of
countries.
A summary of the VEA results is shown in Table 3. As
we mentioned above, the number of efficient countries
drops from 26 (DEA) to 17 (VEA). This means that only 17
countries in the sample are efficient when using weights
that are reasonable for the MPS of their groups. To see how
unreasonable some DEA results can be, the VEA score for
the Democratic Republic of the Congo is just 0.74, whereas
it was completely efficient under the DEA program for the
simple reason that it had the lowest per capita expenditure
on health. Other countries such as Ethiopia or Niger also
fall from complete DEA efficiency to VEA scores under
0.8. The least VEA-efficient country is Swaziland with a
score of 0.47, followed by Zimbabwe (0.49) and Sierra
Leone (0.49). Europe is no longer the most VEA-efficient
geographical area. When consistency in the weights is
required with the VEA program, the average efficiency of
European countries in the upper and lower-middle income
groups falls dramatically. The leading edge of health system
efficiency in the upper-middle income group corresponds to
American and Asian countries, while Oceania obtains the
highest average in the lower-middle income group. Africa
remains the most inefficient area in the three groups in
which it has representative countries. The standard deviation
is also high in Africa and Asia, while it remains moderate in
the rest of the world. The complete results for the 165
countries are provided in Tables 4, 5, 6 and 7.
Now that we have estimated the value of the efficiency
scores for the entire sample, we are interested in testing
whether there is some relationship between the implication
of the public sector in the provision and financing of health
services and the global performance of the system. For this
purpose, we have compiled data on two variables from the
WHO database, namely the “general government expenditure
on health as percentage of total expenditure on health”
(GIMP) and the “general government expenditure on health
as percentage of total government expenditure” (HREL). We
refer to these variables as government implication in health
financing (GIMP) and health relevance in public budgets
(HREL).
Table 8 shows the averages of the variables GIMP and
HREL for the six geographical zones considered and also
the rates of growth of these variables as well as the growth
of per capita expenditure in health (PCEXP) over the period
1995–2004. There is considerable variation among the
countries in the sample with respect to these variables and
their evolution on time. The increase in per capita
expenditure on health (PCEXP) is highest in Europe
(93%), followed by Asia (75%), Africa (68%) and North
America (64%). The growth in Latin America and the
Caribbean and Oceania was moderate at 52%. With respect
to the variable GIMP, Oceania and Europe are the zones
with the largest proportion of the health system publicly
financed (78% and 71%, respectively). In contrast, Asia and
Africa, with 50% and 51% respectively, are the zones with
the lowest public financing. In America the proportion
varies little from the 53% of North America to the 55% of
Latin America and the Caribbean.
Somewhat surprisingly, however, the weight of health in
public budgets (HREL) is greatest in North America (16%),
followed by Europe and Oceania (both with 13%). Again,
these figures contrast with the low figures of 8% and 9% in
Asia and Africa. While this was the situation in 2004, the
evolution since 1995 shows large increases in GIMP,
especially in Africa and Oceania where these figures rose
by 18% and 7%, respectively. The growth of GIMP was
negative in Europe (−3%) and remained almost unchanged
in the rest of the world. Finally, the weight of health in
public budgets (HREL) rose significantly in all zones
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except Latin America and the Caribbean, where this figure
dropped by 5%. Again, the increases were especially
notable in Africa (27%) and Oceania (37%).
From these figures we can conclude that there has been
an evolution towards more public participation in health
financing across the world in recent years, except perhaps
in Europe and Latin America and the Caribbean. It would
therefore be interesting to show the relationship between
these variables (GIMP and HREL) and efficiency in the use
of resources as measured by VEA scores. Before proceeding,
it should be warned that regression analysis is not an
appropriate statistical tool to test the relationship between
DEA or VEA scores and possible explanatory variables. The
reason is that DEA or VEA scores are not normally distributed
n Average Min Max SD Efficient
High income 27 0.964 0.923 1.00 0.02 4
Asia 2 1.00 1.00 1.00 0.0 2
Europe 21 0.963 0.931 1.00 0.02 2
North America 2 0.942 0.924 0.961 0.03 0
Oceania 2 0.967 0.965 0.968 0.00 0
Upper-middle income 50 0.835 0.523 1.00 0.10 4
Africa 7 0.729 0.523 0.855 0.13 0
Asia 13 0.870 0.705 1.00 0.09 2
Europe 11 0.803 0.684 0.873 0.07 0
North America 1 0.883 – – – 0
Latin America and Caribbean 17 0.870 0.737 1.00 0.08 2
Oceania 1 0.823 – – – 0
Lower-middle income 45 0.862 0.469 1.00 0.13 4
Africa 13 0.769 0.470 1.00 0.18 1
Asia 14 0.901 0.729 1.00 0.09 2
Europe 4 0.890 0.816 0.992 0.08 0
Latin America and Caribbean 10 0.890 0.797 0.970 0.05 0
Oceania 4 0.930 0.802 1.00 0.09 1
Low income 43 0.763 0.495 1.00 0.14 5
Africa 31 0.725 0.495 1.00 0.12 2
Asia 11 0.849 0.591 1.00 0.12 2
Oceania 1 1.00 – – – 1
Total 165 0.845 0.470 1.00 0.13 17
Table 3 Summary of VEA
results by income and
geographic areas
Table 4 Complete VEA and DEA results: high income countries
Country VEA score VEA rank DEA score DEA rank Country VEA score VEA rank DEA score DEA rank
Australia 0.968 11 0.968 11 Japan 1.000 1 1.000 1
Austria 0.952 19 0.952 19 Luxembourg 1.000 1 1.000 1
Belgium 0.948 22 0.948 22 The Netherlands 0.949 21 0.949 21
Canada 0.961 13 0.961 13 New Zealand 0.965 12 0.965 12
Czech Republic 0.996 5 0.996 5 Norway 0.960 15 0.960 15
Denmark 0.931 25 0.931 25 Portugal 0.956 18 0.956 18
Finland 0.958 16 0.958 16 Rep. Korea 1.000 1 1.000 1
France 0.960 14 0.960 14 Slovakia 1.000 1 1000 1
Germany 0.958 17 0.958 17 Spain 0.987 6 0.987 6
Greece 0.947 23 0.947 23 Sweden 0.978 7 0.978 7
Hungary 0.949 20 0.949 20 Switzerland 0.976 8 0.976 8
Iceland 0.971 9 0.971 9 UK 0.942 24 0.942 24
Ireland 0.931 26 0.931 26 USA 0.924 27 0.924 27
Italy 0.969 10 0.969 10
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as they are bounded by one. More importantly, the scores are
not IID. Therefore, non-parametric rank-based tests are
preferable. For further discussion about the application of
non-parametric rank-based statistics to efficiency scores, see
Brockett and Golany (1996) and Sueyoshi and Aoki (2001).
We ranked countries based on their VEA score and then
assigned them to five efficiency groups of equal size (N=33).
Then, we used the Kruskal-Wallis non-parametric test (H-
KW) to test for the existence of significant differences across
the five efficiency groups with respect to the variables that
reflect the government role in the health system. Table 9
shows the average values for the VEA score and the
variables of government implication (GIMP) and health
relevance in public budgets (HREL). It is clear from the table
that the most efficient groups of countries also have a higher
government implication in financing health services. In the
most efficient countries (group 5), an average of 63.8% of
health expenditure is public expenditure, which means that
almost two thirds of the system has a public basis. In
contrast, low efficiency countries show an average of public
expenditure on health of around 50%. The differences across
groups are statistically significant at the 0.1 level. The
relevance of health expenditure within the government
budget seems also to be positively associated with the
performance of the health system. The most efficient
countries dedicate averages of above 11% of the government
budget to the health system, while this figure drops to 10%
or 9% in countries with lower efficiency scores. However,
these differences are not statistically significant at conven-
tional levels. All in all, the results suggest that having a high
percentage of the health system publicly financed also
creates a more efficient system. Similar results are obtained
if we use the DEA scores instead of the VEA scores to
construct the five efficiency groups.
Concluding remarks
This paper provides additional evidence on the lack of
discriminatory power of DEA when the weights of inputs
and outputs in the linear programs are freely selected for
DMUs. There are three ways to improve the discriminatory
power of DEA. First, the simplest procedure is to reduce
the number of input-output dimensions to be considered in
Table 5 Complete VEA and DEA results: Upper-middle income countries
Country VEA score VEA rank DEA score DEA rank Country VEA score VEA rank DEA score DEA rank
Argentina 0.737 45 0.932 31 Libya 0.764 39 0.973 14
Bahrain 0.797 34 0.939 28 Lithuania 0.741 42 0.932 32
Barbados 0.765 38 0.947 26 Malaysia 0.877 15 0.950 24
Belarus 0.778 37 0.916 35 Malta 0.848 26 1.000 1
Belize 0.822 32 0.914 37 Mauritius 0.833 29 0.933 30
Botswana 0.523 50 0.530 50 Mexico 0.883 14 0.968 17
Brazil 0.740 43 0.883 44 Oman 1.000 1 1.000 1
Brunei 0.894 13 0.984 10 Panama 0.894 12 0.985 9
Bulgaria 0.866 22 0.960 22 Poland 0.813 33 0.965 20
Chile 0.902 11 0.998 7 Qatar 0.907 10 0.967 19
Costa Rica 1.000 1 1.000 1 Romania 0.873 17 0.952 23
Croatia 0.870 19 0.967 18 Russia 0.764 40 0.875 45
Cyprus 0.871 18 0.976 12 St. Kitts and Nevis 0.868 20 0.916 36
Dominica 0.874 16 0.964 21 Saint Lucia 0.864 23 0.950 25
Eq. Guinea 0.838 28 0.838 47 St. Vinc. and Grenada 0.919 9 0.923 33
Estonia 0.751 41 0.944 27 Saudi Arabia 0.847 27 0.914 38
Fiji 0.823 31 0.900 40 Seychelles 0.855 25 0.905 39
Gabon 0.701 47 0.786 48 Slovenia 0.684 48 0.973 13
Grenada 0.867 21 0.889 43 South Africa 0.587 49 0.653 49
Israel 0.790 35 1.000 1 Suriname 0.856 24 0.896 42
Jamaica 1.000 1 1.000 1 Trinidad and Tobago 0.933 7 0.935 29
Kazakhstan 0.705 46 0.858 46 Turkey 0.986 5 0.986 8
Kuwait 1.000 1 1.000 1 United Arab Emirates 0.922 8 0.969 16
Latvia 0.739 44 0.922 34 Uruguay 0.782 36 0.971 15
Lebanon 0.827 30 0.898 41 Venezuela 0,961 6 0.981 11
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the model specification. The cost of this approach is that
information that may be relevant to discrimination is
overlooked. Second, the sample size may be increased.
Theoretically, this would be the best solution although,
unfortunately, it may be not feasible (in practice) when the
researcher is working with complete populations, as is often
the case. A third approach is to improve the discriminatory
power of the model by supplying some additional informa-
tion on how the discrimination should be carried out. Value
efficiency analysis (VEA) was developed in order to easily
incorporate a piece of qualitative information into the DEA
specification. This information corresponds to the identifica-
tion of a most preferred solution (MPS) that acts as an ideal
weighting reference in the eyes of an expert. Our results show
that VEA significantly increases the discriminatory power of
DEA and achieves congruence in the weights of inputs and
outputs.
The paper applied both DEA and VEA methodologies to
health data on a sample of 165 countries during the year
2004. The sample includes all the countries for which we
were able to compile the required data on inputs and
outputs. Our sample comprises nearly the whole population
of countries in the world (around 86%). Thus, it is not
possible to significantly improve the discriminatory power
of DEA by increasing the sample size. The DEA scores
show moderately high levels of efficiency in health
provision, with an average of 0.91. However, VEA analysis
shows an average of only 0.84 when consistency in shadow
prices is forced into the measurement model. By simply
incorporating information on an efficient country that is
considered as an appropriate general referent for the
weights (MPS) within each group of countries, VEA
notably increases the discriminatory power of DEA.
From 26 DEA-efficient countries, we obtain just 17
VEA-efficient referents. What is happening is that VEA
allows a simple identification of the countries whose DEA
score is based on unrealistic values for the shadow prices of
inputs and outputs. These countries (Democratic Republic
of the Congo or Ethiopia, for instance) benefit from the
extreme flexibility of DEA, but do not withstand any
further analysis of their activity data. For example, a DMU
may obtain a DEA score of 1 simply because it is the unit
that produces the largest quantity of an output, thus
assigning a very large weight to that variable. VEA does
not allow this extreme flexibility with regard to weights.
Behavior must be globally acceptable, and the MPS
indicates what is considered as globally acceptable behavior
in terms of weighting inputs and outputs.
Table 6 Complete VEA and DEA results: Lower-middle income countries
Country VEA score VEA rank DEA score DEA rank Country VEA score VEA rank DEA score DEA rank
Albania 0.917 19 0.976 14 Jordan 0.782 37 0.948 26
Algeria 1.000 1 1.000 1 Kiribati 0.802 35 0.838 41
Angola 0.585 43 0.929 31 Lesotho 0.518 44 0.536 45
Armenia 0.957 11 0.974 16 Maldives 0.729 40 0.898 36
Azerbaijan 0.947 14 0.955 24 Mongolia 0.934 16 0.934 28
Bhutan 0.914 20 0.958 23 Morocco 0.955 12 0.992 10
Bolivia 0.865 28 0.882 38 Namibia 0.586 42 0.684 43
Cameroon 0.706 41 0.756 42 Nicaragua 0.970 8 0.989 11
Cape Verde 0.978 7 0.986 12 Paraguay 0.928 17 0.962 20
China 0.995 5 1.000 1 Peru 0.954 13 0.963 19
Colombia 0.797 36 0.966 17 Philippines 0.946 15 0.959 22
Congo 0.820 33 1.000 1 Rep. Moldova 0.992 6 0.992 9
Djibouti 0.756 39 1.000 1 Samoa 0.958 10 0.961 21
Dominican Rep. 0.874 25 0.926 33 Sudan 0.848 29 1.000 1
Egypt 0.904 22 0.922 34 Swaziland 0.470 45 0.562 44
El Salvador 0.870 27 0.929 32 Thailand 0.897 23 0.933 29
Georgia 1.000 1 1.000 1 Macedonia 0.837 32 0.986 13
Guatemala 0.881 24 0.933 30 Timor-Leste 0.840 31 0.845 40
Guyana 0.841 30 0.875 39 Tonga 0.961 9 0.964 18
Honduras 0.919 18 0.937 27 Tunisia 0.873 26 0.974 15
India 0.913 21 0.950 25 Ukraine 0.816 34 0.920 35
Indonesia 1.000 1 1.000 1 Vanuatu 1.000 1 1.000 1
Iran 0.767 38 0.895 37
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Table 7 Complete VEA and DEA results: low income countries
Country VEA score VEA rank DEA score DEA rank Country VEA score VEA rank DEA score DEA rank
Afghanistan 0.591 38 0.819 25 Mali 0.679 31 0.712 36
Bangladesh 0.929 6 0.972 11 Mauritania 0.795 17 0.815 27
Benin 0.754 23 0.800 28 Mozambique 0.643 35 0.677 38
Burkina Faso 0.753 24 0.910 16 Nepal 0.851 11 0.919 13
Burundi 0.647 34 0.913 15 Níger 0.749 25 1.000 1
Cambodia 0.726 29 0.798 29 Nigeria 0.674 33 0.753 33
Chad 0.732 27 0.783 31 Pakistan 1.000 1 1.000 1
Comoros 1.000 1 1.000 1 Rwanda 0.622 36 0.677 37
Côte d'Ivoire 0.698 30 0.751 34 San Tome and Principe 0.819 15 0.918 14
D. R. Congo 0.743 26 1.000 1 Senegal 0.871 9 0.898 18
Eritrea 1.000 1 1.000 1 Sierra Leone 0.496 42 0.537 43
Ethiopia 0.780 19 1.000 1 Solomon I. 1.000 1 1.000 1
Gambia 0.856 10 0.902 17 Tajikistan 0.910 7 0.984 10
Ghana 0.846 12 0.893 19 Togo 0.730 28 0.796 30
Guinea 0.777 20 0.815 26 Uganda 0.617 37 0.725 35
Guinea-Bissau 0.761 22 0.844 23 Tanzania 0.764 21 0.868 22
Kenya 0.679 32 0.780 32 Uzbekistán 0.904 8 0.990 9
Kyrgyzstan 0.832 13 0.956 12 Viet Nam 1.000 1 1.000 1
Lao PDR 0.786 18 0.832 24 Yemen 0.808 16 0.870 21
Liberia 0.557 40 0.645 39 Zambia 0.590 39 0.638 40
Madagascar 0.824 14 0.890 20 Zimbabwe 0.495 43 0.569 42
Malawi 0.544 41 0.623 41
2004 Growth 1995–2004
GIMP HREL GIMP HREL PCEXP
Africa 51.5 9.2 18.6 27.3 68.9
Asia 50.0 7.9 −0.6 7.6 75.8
Europe 71.2 13.5 −3.3 19.9 93.0
North America 53.8 16.3 2.5 18.6 64.7
Latin America and Caribbean 55.2 1,136 −0.3 −5.4 52.7
Oceania 78.3 13.3 7.7 37.2 52.1
Total 57.4 10.6 5.2 15.9 72.3
Table 8 Trends in government
financing of health throughout
the world
Group 1 Group 2 Group 3 Group 4 Group 5 H-KW
N 33 33 33 33 33
VEA score 0.64 0.79 0.87 0.94 0.99
GIMP 50.4 56.6 57.9 58.2 63.8 2.01a
HREL 10.5 9.3 10.3 11.0 11.7 1.49
Table 9 Government role in
the health system and
performance
a Significance level 0.1
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We followed an innovative approach to objectively
selecting the MPS. This involves the estimation of VEA
scores using each of the 26 DEA-efficient countries as the
MPS. Then, the reduction in the average dispersion of the
weights of inputs and outputs within each group of
countries is computed, and the country that achieves the
highest reduction in dispersion is selected as the MPS for
that group. Using this method, Japan (high income), Oman
(upper-middle income), Algeria (lower-middle income) and
Solomon Islands (low income) were selected as the MPSs
of the four groups of countries. They achieve reductions of
15%, 77%, 70% and 69% in the coefficients of variation of
the weights in their respective groups of countries. Thus,
the improvement in the discriminatory power of VEA is
obtained through a more rational selection of weights in the
mathematical programs.
A look at the scores shows that high income countries
lead the efficiency edge of health provision in terms of
efficiency, while low income countries have the lowest
efficiency scores on average. By geographical regions,
North America and Oceania achieve the highest averages in
the VEA scores, while Africa shows the poorest results.
There are, of course, rich countries that also show important
inefficiencies. The USA, for instance, has a score of just
0.92, which means that an 8% improvement in health
outcomes could be achieved without increasing resources
deployed to the health system. Denmark, the UK and the
Netherlands are other examples of rich countries with VEA
scores below 0.95. This means that considerable resources
that are devoted to health do not have the desired impact on
health outcomes within these countries. The results are
consistent with the flat-of-the-curve medicine hypothesis
that predicts the moderate marginal impact on average
health outcomes from additional investments in health in
rich countries. However, the most worrying fact is the
confirmation that poor countries with poor health outcomes
are also the countries that use the scant resources they
devote to health in the most inefficient manner, especially
in Africa.
The role of governments in financing the health system is a
controversial issue. It is commonly stated that private health
insurance tends to incur higher management and administra-
tive costs than statutory health insurance (Thomson and
Mossialos 2004). The need to generate a profit is another
opportunity cost that public systems do not incur. Our results
partially support public financing of health services. The
most efficient countries in our sample have around 64% of
the health system publicly financed, while the least efficient
countries barely reach 50%. The weight of health in the
government budget is also positively associated with
efficiency, but in this case the association is not statistically
significant at conventional levels. However, we can conclude
that the countries in which governments show a deeper
commitment to the development and financing of the health
system also use the resources more efficiently in the
achievement of relevant health outcomes.
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